Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A. Hanania, John G. Matthews, Mark D. Eisner et al.|The Lancet Respiratory Medicine|2016Cited by 465